PCVX Q2 2021 Earnings — Vaxcyte, Inc. Revenue & Financial Results | Market Cap Arena

PCVXVaxcyte, Inc.

$9B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$24M

Net Income

-$24M

EPS (Diluted)

$-0.46

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$31M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$358M

Total Liabilities

$41M

Stockholders' Equity

$317M

Cash & Equivalents

$151M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$24M	-$21M	-11.8%
Net Income	-$24M	-$20M	-16.5%

Revenue Segments

Pneumococcal Conjugate Vaccine

$7.0B100%